title: Longevity of effects of hyaluronic acid plus lidocaine facial filler.
abstract: BACKGROUND
  A new hyaluronic acid filler containing pre-incorporated 0.3% lidocaine reduces pain and enhances patient comfort. In vitro studies confirm functional equivalence with non-lidocaine-containing products, but only limited data are available on the long-term effects of lidocaine on filler performance in the clinical setting.
  
  
  OBJECTIVE
  To investigate whether inclusion of lidocaine impacts the longevity of hyaluronic acid fillers.
  
  
  METHODS
  60 patients with moderate-severe bilateral nasolabial folds received 24 mg/mL hyaluronic acid with pre-incorporated lidocaine or an equivalent product without lidocaine and were followed-up for up to 76 weeks.
  
  
  RESULTS
  Significantly better results were found in favor of HA gel with pre-incorporated lidocaine for physician assessment of injection pain and patient pain assessment after injection (both P < 0.001). Long-term follow-up of patients after almost a year showed that 91% (52/57) of patients had no evidence of facial asymmetry, and investigators confirmed lidocaine had no effect on filler longevity. High levels of patient satisfaction and prolonged benefits due to persistence of the product were noted, with those patients needing additional treatment requiring 'top-up' rather than full re-treatment.
  
  
  CONCLUSIONS
  The addition of 0.3% lidocaine does not affect product longevity and the small volume required for 'touch-up' also suggests that longevity is maintained.
authors.affiliation: Facial Plastic Surgery Centre, Cannes, France. raspaldo@clinic.com.fr
authors.forename: Hervé
authors.initials: H
authors.lastname: Raspaldo
authors.forename: Koen
authors.initials: K
authors.lastname: De Boulle
authors.forename: Phillip M
authors.initials: PM
authors.lastname: Levy
mesh_terms: D000328:Adult; D000368:Aged; D003879:Dermatologic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D004311:Double-Blind Method; D004338:Drug Combinations; D005060:Europe; D005145:Face; D005260:Female; D005500:Follow-Up Studies; D005602:France; D005782:Gels; D006801:Humans; D006820:Hyaluronic Acid / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D007271:Injections, Intradermal; D008012:Lidocaine / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D017060:Patient Satisfaction; D011446:Prospective Studies; D012060:Rejuvenation; D015595:Skin Aging / Q000187:drug effects*; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D003879:Dermatologic Agents; D004338:Drug Combinations; D005782:Gels; D006820:Hyaluronic Acid; D008012:Lidocaine